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Can molecular imaging
techniques identify
biomarkers for
neuropsychiatric
disorders?
Podem as técnicas de
imagem molecular
identificar biomarcadores
nos distúrbios
neuropsiquiátricos?
The phenomenological paradigm used for neuropsychiatric
diagnosis is still hegemonic in the currently adopted classifications.
This paradigm, however, has the particular caveat of not including
any information from biological or pathophysiological mechanisms.
With recent advances in the methods for clinical neurosciences
investigations, promising new approaches to investigate the
pathophysiology of neuropsychiatric disorders (NPD) have become
available and are now leading to studies that attempt to unravel
the neurobiological underpinnings of these diseases. Advances
in molecular imaging techniques, such as positron emission
tomography (PET) and single photon emission computerized
tomography (SPECT), have made important contributions to the
understanding of the pathophysiology of NPD. These techniques
use radiolabeled tracers, which allow direct investigation of
neuroreceptors in vivo at any stage of the NPD. More sensitive
than neuroanatomical imaging techniques, molecular imaging
approaches are able to identify subtle cerebral pathophysiological
changes before neurostructural abnormalities take place.
One of the major goals of molecular imaging research has
been the identification of biomarkers, which are defined as the
characteristics that are objectively measured and can differentiate
normal biologic processes from pathogenic processes. These
approaches are at a privileged condition to potentially provide
accurate and early NPD recognition, evaluate disease progression,
and monitor treatment efficacy. In recent years, attention has
been turned to individuals at risk of developing NPD aiming to
prevent the progression of these disorders. Biomarkers, as
indicators of underlying biological processes, offer the potential
to identify asymptomatic individuals who will develop the NPD in
the following years.
An example of the use of PET and SPECT to identify biomarkers
of NPD are the dopamine transporter (DAT) radiotracers that
evaluate dopamine neuronal loss in Parkinson’s disease (PD).
The DAT are located in the axon terminals of nigrostriatal dopamine
neurons located in the striatum and are expected to decrease
with the dopaminergic neurodegeneration observed in PD. Several
receptor-imaging studies have shown that PD patients have
decreased DAT when compared to matched controls (for review
see Ravina et al., 2005).1 We have recently performed a study
with similar results in Brazil.2-3 The studies have consistently
shown a negative correlation between DAT density and PD
progression. Figure 1 shows several SPECT brain images of PD
patients at the level of the striatum (higher color intensity means
higher DAT density). The images were acquired from patients
with increasing PD severity as measured with Hoehn & Yahr
scale. The decrease in DAT density with the progression of PD is
evident in these scans.
Current diagnosis of PD still relies on subjective clinical criteria,
which include bradykinesia, and at least one of other three core
symptoms (resting tremor, postural instability, and rigidity). This
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makes it difficult to differentiate PD from other movement
disorders, such as essential tremor, especially at early stages of
PD. Studies using TRODAT and SPECT have shown impressive
diagnostic accuracy, with specificity higher than 97% and
sensitivity greater than 91%.
The higher DAT decrease in PD is in fact related to an advanced
stage of neuronal loss. DAT loss observed in SPECT and PET
can be seen even before the beginning of symptoms, since
clinical manifestations take place after more severe dopamine
neuron deterioration.
Another important example of the potential clinical utility of
molecular imaging is the development of new radiotracers for
Alzheimer’s disease. Mounting efforts have been directed to the
development of new treatment strategies to prevent or at least
delay Alzheimer’s disease progression through early interventions.
Currently, combination of clinical and neuroanatomical imaging
criteria provides reasonable sensitivity and specificity for the
diagnosis of Alzheimer’s disease only at mid or late stages but
not at early stages. Molecular imaging radiotracers that bind to
plaque and tangles can potentially identify Alzheimer’s disease
patients before clinical manifestation of the disease. Recent studies
using a PET radiotracer ([18F]FDDNP) for plaque and tangles
were able to differentiate among patients with Alzheimer’s disease,
mild cognitive impairment and healthy controls.4 This is one of
the first studies to identify patients with mild cognitive impairment,
who are at a transitional stage between normal aging and
Alzheimer’s disease. However, this diagnosis refers to a presumed
underlying pathophysiological state, but the course of the condition
is heterogeneous. Therefore, more studies validating the tracer
are necessary to fully implement the method in clinical settings.
 In psychiatric disorders such as schizophrenia, molecular
imaging techniques have provided some of the most relevant
pathophysiological evidence of the dopaminergic dysfunction
in vivo in drug free patients (for review see Bressan et al.,
2001).5 Initial efforts focused on D
1
 and D
2 
receptor density
changes, but failed to show differences between patients and
controls. More recently, the research groups endeavored
dopamine function a more relevant challenge. They have
produced several studies showing increased DOPA decarboxylase
activity using [18F]-FDopa or [11C]-dopa, higher dopamine release
after using amphetamine challenges and [11C]-raclopride or [123I]-
IBZM, and higher concentration of dopamine in the synaptic
cleft using alpha-methyl-paratyrosine challenges and [123I]-
IBZM.5 Although the f indings are extremely relevant,
demonstrating an increased dopamine activity in schizophrenia,
these methods have not developed into biomarkers due to the
high complexity of the disorder and low sensitivity and specificity
of the findings.
Despite their considerable promise for application in the
investigation of NPD, biomarkers still have limited utility in clinical
practice. Recent studies are using a more powerful strategy
combining several biological markers at the same time, including
genetics, structural neuroimaging, neuropsychology,
neuroendocrinology, and molecular imaging. This strategy can
provide hundreds of thousands of variables, and some
combinations of variables may provide more robust biomarkers to
be used in clinical practice. These biomarkers may identify the
underlying biological processes of NPD before the onset of
symptoms and offer the opportunity to prevent the occurrence of
devastating disorders.
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